Novogen patent prompts Solae suit

- Last updated on GMT

Related tags: License, Solae

US- and Australia-based biotech firm Novogen has been granted a US
patent covering health supplements based on the use of soy
isoflavones in tablet or capsule form.

The patent has been licensed worldwide, with the exception of Australia and New Zealand, to the recently formed soy ingredients business Solae, a joint venture between DuPont and Bunge.

The patent has prompted Solae to issue a new patent infringement suit in the US against both Archer Daniels Midland and Amerfit.

Novogen​, which also develops pharmaceutical products, already holds a number of US patents for technology for the production of isoflavones and also markets its own proprietary supplements - Promensil, for the treatment of the symptoms of menopause, Rimostil for the maintenance of bone and cholesterol health in post-menopausal women and Trinovin for the maintenance of prostate and urinary health for men.

It has been receiving royalty payments from Solae for some months for licensing part of its technology to DuPont.

Related topics: Proteins

Related products

show more

Say Cheese To Vegan

Say Cheese To Vegan

Webinar

Consumers have numerous expectations on plant-based cheese. A strong demand to meet an immediate consumer need for high quality in terms of taste and texture...

Register for free

18 steam distillation challenges solved!

18 steam distillation challenges solved!

BÜCHI Labortechnik AG | 09-Nov-2021 | Technical / White Paper

Use our popular steam distillation cue cards to benefit from expert solutions to key challenges in steam distillation.

Related suppliers

Follow us

Products

View more

Webinars